SIMCERE PHARMA Enters Exclusive Licensing Deal with Ipsen, Potentially Worth Up to US$1.06 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: aastocks
Licensing Agreement: SIMCERE PHARMA's subsidiary, Jiangsu Zaiming, has signed an exclusive licensing agreement with Ipsen Pharma SAS for the global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside of Greater China.
Financial Terms: The agreement includes potential earnings of up to US$1.06 billion for SIMCERE PHARMA, consisting of a US$45 million upfront payment and additional milestone payments, along with tiered royalties on sales contingent on successful development and regulatory approvals.
Analyst Views on 02096
Wall Street analysts forecast 02096 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02096 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.470
Low
Averages
High
Current: 11.470
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
